Myovant Sciences to Participate at Upcoming Investor Conferences
September 02 2022 - 6:45AM
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company
that aspires to redefine care for women and for men through
purpose-driven science, empowering medicines, and transformative
advocacy, today announced that David Marek, Chief Executive Officer
of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and
Business Officer, will participate in the following upcoming
investor conferences:
- Citi's 17th
Annual BioPharma Conference on Thursday, September 8,
2022. Management will participate in one-on-one investor
meetings.
- Baird 2022
Global Healthcare Conference on Tuesday, September 13,
2022 at 12:15 p.m. Eastern Time, Mr. Marek and Mr. Mehra will
participate in a fireside chat. Management will also participate in
one-on-one investor meetings on September 13.
Investors and the general public are invited to listen to the
Baird fireside chat, which will be accessible on the Events page
under the Investors & Media section of
the Myovant website at www.myovant.com.
ABOUT MYOVANT SCIENCESMyovant
Sciences aspires to redefine care for women and for men
through purpose-driven science, empowering medicines, and
transformative advocacy. Founded in 2016, Myovant has
executed five successful Phase 3 clinical trials across oncology
and women’s health leading to three regulatory approvals by
the U.S. Food and Drug Administration (FDA) for men with
advanced prostate cancer, women with heavy menstrual bleeding
associated with uterine fibroids, and pre-menopausal women with
moderate to severe pain associated with endometriosis,
respectively. Myovant also has received regulatory
approvals by the European Commission (EC) and
the United Kingdom Medicines and Healthcare Products
Regulatory Agency (MHRA) for women with symptomatic uterine
fibroids and for men with advanced hormone-sensitive prostate
cancer. Myovant has a supplemental New Drug Application under
review with the FDA for updates to the United States Prescribing
Information (USPI) based on safety and efficacy data from the Phase
3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in
premenopausal women with heavy menstrual bleeding due to uterine
fibroids for up to two years. Myovant also is conducting
a Phase 3 study to evaluate the prevention of pregnancy in women
with uterine fibroids or endometriosis. Myovant also is
developing MVT-602, an investigational oligopeptide kisspeptin-1
receptor agonist, which has completed a Phase 2a study for female
infertility as part of assisted reproduction. Sumitovant
Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co.,
Ltd., is Myovant’s majority shareholder. For more information,
please visit www.myovant.com. Follow @Myovant on
Twitter and LinkedIn.
Investor Contact: Uneek MehraChief Financial
and Business OfficerMyovant Sciences, Inc.investors@myovant.com
Media Contact:Noelle Cloud DuganVice President,
Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Jul 2023 to Jul 2024